Pfizer remains a strong buy due to its undervalued stock, robust drug pipeline, and aggressive growth in oncology and obesity treatments. The company reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and EPS of $2.8–$3 despite patent expirations. Key strategies include onshoring high-margin production and aggressive cost-cutting to mitigate risks from patent losses and improve operating margins through 2027. With a price-to-earnings ratio of 8.13 and a 6.4% dividend yield, Pfizer offers compelling value compared to peers, though risks remain around patent cliffs and execution of its obesity platform.
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The iShares Select Dividend ETF (DVY) provides a reliable income stream with a trailing yield of about 3.5%, sourced from dividends of roughly 100 U.S. companies known for stable payouts. Its portfolio focuses on defensive sectors like utilities, fin...
The Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) provides monthly income with a current 4.5% yield, focusing on stable, high-yield stocks from the S&P 500. Its dividends come from real cash flows of companies like Pfizer and Verizon, thoug...
Pfizer's aggressive mergers and acquisitions combined with in-house research and development have driven its growth portfolio to generate $3.1 billion in revenues in the first quarter of 2026, a 22% operational increase year-over-year. The risk from ...
